Manuel Monreal/X
Aug 31, 2025, 07:05
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal, coordinator of the RIETE registry, posted on X:
”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers
No major differences in GU or CI cancers
Should all cancer patients with acute VTE receive the same treatment strategy?”
Find it here.
Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis
Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal
Stay updated with Hemostasis Today.
Aurora Villalobos
Behnood Bikdeli
Bleeding Risk
cancer
Cihan Ay
David Jimenez
Hematology
Hemostasis Today
Javier Pagán-Escribano
Javier Trujillo-Santos
Luciano López-Jiménez
Manuel Monreal
Maurizio Ciammaichella
Montserrat Pérez-Pinar
PE
Pulmonary embolism
RIETE registry
venous thromboembolism (VTE)
-
Jan 29, 2026, 14:02Emma Lefrancais on Alarmin IL33 and Platelet Biology
-
Jan 29, 2026, 13:44Sia A: One of My Favorite Conversations from ASH
-
Jan 29, 2026, 13:34Sarah Matuja on Tanzania Stroke Project
-
Jan 29, 2026, 13:28Nancy Di Salvo on Amplifying Rare Disease Voices Through Partnership
-
Jan 29, 2026, 13:21Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS